Clinical Trial Detail

NCT ID NCT03856216
Title Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplant
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lymphoma

acute lymphoblastic leukemia

Therapies

Methotrexate

Filgrastim + Methotrexate + Rituximab

Rituximab

Bendamustine + Fludarabine + Inotuzumab ozogamicin + Tacrolimus

Filgrastim + Methotrexate

Inotuzumab ozogamicin

Fludarabine + Inotuzumab ozogamicin + Melphalan + Tacrolimus

anti-thymocyte globulin

Age Groups: adult senior

No variant requirements are available.